Amneal Pharmaceuticals, Inc. Stock News

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.19 per share a year ago.

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amneal has more than 270 products. On Tuesday, the company launched a generic for Xyrem to treat excessive daytime sleepiness.

Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.

The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals' drug for Parkinson's disease due to inadequate safety data on the treatment to help control symptoms in pati

Penny stocks to watch under $5. The post Best Penny Stocks To Buy Now?

Hot penny stocks with big news this week. The post 3 Top Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Amneal Pharmaceuticals Inc.'s stock AMRX, -2.16% soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter guidance that topped consensus est

CNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?

Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences:

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2022 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Chirag Patel - Co-Founder, Co-Chief Executive Officer Chintu Patel - Co-Foun